AAMU
URGN icon

Amundi Asset Management US’s UroGen Pharma URGN Stock Holding History

Amundi Asset Management US’s Portfolio URGN Stock Details URGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,000
Closed -$94K – 1667
2018
Q3 		$94K Buy
2,000
+900
+82% +$41.8K ﹤0.01% 1522
2018
Q2 		$55K Hold
1,100
– – ﹤0.01% 1512
2018
Q1 		$55K Hold
1,100
– – ﹤0.01% 1483
2017
Q4 		$41K Buy
+1,100
New +$39.2K ﹤0.01% 1516

Other funds holding URGN

MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HCM
Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Amundi Asset Management US's URGN Position: Q4 2018 in Review

Amundi Asset Management US sold out of UroGen Pharma (URGN) in Q4 2018, closing a stake of 2,000 shares — an estimated $94K sold.

Amundi Asset Management US first reported a position in URGN in Q4 2017 and held it in 4 quarters. The position peaked at $94K in Q3 2018. 63 funds tracked by Wall St. Rank hold URGN as of Q4 2018.

  • Amundi Asset Management US reported no remaining UroGen Pharma position as of Q4 2018 after selling out during the quarter.
  • Amundi Asset Management US sold 2,000 UroGen Pharma shares in Q4 2018, an estimated $94K.
  • Amundi Asset Management US first reported a position in UroGen Pharma in Q4 2017 and held it in 4 quarters.
  • Amundi Asset Management US's UroGen Pharma position peaked at $94K in Q3 2018.
  • 63 funds tracked by Wall St. Rank held UroGen Pharma as of Q4 2018.

Based on Amundi Asset Management US's 13F filing for Q4 2018, filed 14 Feb 2019.